• Page Amit B. Department of Pharmacology, School of Pharmacy and Technology Management, NMIMS, Shirpur (M.S.), India
  • Kulkarni Kala S. Department of Pharmacology, School of Pharmacy and Technology Management, NMIMS, Shirpur (M.S.), India


Boswellia serrata, Camellia sinensis, Safety, Angiogenesis, CAM, Angiogenesis dependent disease, Arthritis, Metastasis


Objective: The process of angiogenesis is finely balanced by Proangiogenic factors and antiangiogenic factors. Any imbalance between these factors may result in a group of diseases with varied morphologic and pathologic changes, called angiogenesis dependent diseases. One has to arrest the growth of unwanted blood vessels like in metastasis of tumour, arthritis, retinopathies, etc. As the angiogenesis is simultaneously controlled by several factors, one needs to target the whole process through a holistic approach i.e. targeting more than one mechanism at a time. Objective of our study was to evaluate antiangiogenic potentials of Camellia sinensis and Boswellia serrata in whole animal models along with their safety individually as well as in combination.

Methods: These extracts were evaluated for their antiangiogenic effect using three models – Chicken Chorioallentoic membrane assay, Rat Subcutaneous air sac and Mesenteric window angiogenesis.

Results: The results of toxicity study showed that aqueous extracts of Camellia sinensis and Boswellia serrata are safe on oral administration in acute as well as repeated dose toxicity studies. It also showed antiangiogenic effects of individual extracts as well as their combinations. The study suggests that there may be synergistic effect in these extracts particularly in mesenteric window model.

Conclusion: From the study it can be concluded that these extracts can be clinically evaluated on angiogenesis dependent diseases.


Download data is not yet available.


Folkman Judah, Shing Yuen. Angiogenesis J. Biol. Chem. 1992, 267 (16):10931-10934.

Folkman Judah. What Is Evidence That Tumours Are Angiogenesis Dependent? Journal of National Cancer Institute. 1990, 82 (1):4-6.

Mauriz S L., Javier Gonzalez-Gallego. Antiangiogenic Drugs:Current Knowledge and New Approaches to Cancer Therapy. J. Pharm. Sci.;2008, 97:4129-54.

Ezaz Sohail Anti-Angiogenic activities associated with exposure of environmental smoke solutions from 2-stroke auto-rikshow. Environmental Toxicology and Pharmacology. 2009, 28:42-51.

Felmeden D. C., Blann A.D., Lip G.Y.H. Angiogenesis:Basic Pathophysiology and Implications for Disease. E. Heart J.2003, 24:586-603

Tortora Giampaolo, Davide Melisi, Fourtunato Ciardiello. Angiogenesis:A Target for Cancer Therapy. Current Pharmaceutical Design;2004, 10:11-26.

Tabibiazer R. and Rockson S. G.. Angiogenesis and the Ischemic Heart. European Heart Journal. 2001, 22:903-18.

De – En Hu, Comparative Studies of the Angiogenic Activity of Vasoactive Intestinal Peptide, Endothelins-1 and-3 and Angiotensin II in Rat Sponge Model. British Journal of Pharmacology. 1996, 117:545-51.

Ribatti D., Angiogenesis Extent and Expression of Matrix Metalloprotinase – 2 and-9 Correlate with Progression in Human Neuroblastoma. Life Sciences. 2001, 68:1161 – 68.

Harris A. L. Angiogenesis as a New Target for Cancer Control. EJC Supplements. 2003, 1 (2):1-12.

Daniel J. George, Cassandra Moore. Angiogenesis Inhibitors in Clinical Oncology. Update on Cancer Therapeutics. 2006, 1:429 – 34.

Ferrara Napoleone, Hillan Keneth J., Novotny William. Bevasizumab (Avastin), a Humanised anti-VEGF Monoclonal Antibody for Cancer Therapy. Biochemical and Biophysical Research Communications. 2005, 333:328–35.

Liekens Sandra, Eric De Clercq, Johan Neyts. Angiogenesis:Regulators and Clinical Applications. Biochemical Pharmacology. 2001, 61:253–70

Tan Mei Lin, Chung Peter F M, Dass Crispin R. Doxorubicin Delivery Systems Based on Chitosan for Cancer Therapy. Journal of Pharmacy and Pharmacology. 2009, 61:131-42.

Xiong Xiao-Bing Multifunctional Polymeric Micelles for Enhanced Intracellular Delivery of Doxorubicin to Metastatic Cancer Cells. Pharmaceutical Research. Nov.2008, 25 (11):2555-66.

D’Souza Gerard G M Surface Modification of Pharmaceutical Nanocarriers with Ascorbate Residues Improves their Tumour-Cell Association and Killing and the Cytotoxic Action of Encapsulated Paclitaxel In Vitro. Pharmaceutical Research. Nov.2008, 25 (11):2567-72.

Perva –Uzunalc A., Skerget M., Knez Z., Weinreich B., Otto F., Gruner S.,. Extraction of active ingredients from gren tea (Camellia sinensis):Extraction efficiency of major catechins and caffeine. 2006, 96:597-605.

Marinova D., Ribarova F., Atanassova M. Total Phenolocs and Total Flavonoids in Bulgerian Fruits and Vegetables. J Uni Chem Tech Metall 2005, 40:255-260.

The Organisation for Economic Co-Operation and Development (OECD), Test No. 423, Acute Oral Toxicity – Acute Toxic Class Method, in OECD Guidelines for Testing of Chemicals Section 4:Health Effects, OECD publishing,2002.

The Organisation for Economic Co-Operation and Development (OECD), Test No. 408, Repeated 90-day Oral Toxicity Study in Rodents, in OECD Guidelines for Testing of Chemicals Section 4:Health Effects, OECD publishing,1998.

Nguyen M., Yoo Y.C., Folkman J. Quantitation o f angiogenesis and antiangiogenesis in chick embryo Chorioallentoic membrane. Microvascular Research. 1994, 47:31-40.

Lichtenberg J., Hansen C. A., Skak-Nilsen T., Bay C., Mortensen J.T., Binderup L. The rat subcutaneous air sac model:a new and simple method for in vivo screening of antiangiogenesis. Pharmacol Toxicol 1997, 81:280–84.

Norrby K. Evidence of a dual role of endogenous histaminein angiogenesis. Int J Exp Pathol 1995, 76:87–92.



How to Cite

B., P. A., and K. K. S. “STUDY OF CAMELLIA SINENSIS AND BOSWELLIA SERRATA IN RESPECT TO ANTIANGIOGENIC EFFECT”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 7, July 2014, pp. 542-6,



Original Article(s)